Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and ...
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, ...
Key Takeaways GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and ...
The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
(Bloomberg) -- GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline. The British drugmaker boosted its 2031 ...
Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...
Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback